A new paper is getting attention because it links two things a lot of people are already talking about: GLP-1 medications and Botox / anti-wrinkle treatments.
So, is there actually anything in it?
Possibly, yes, but it needs putting into context properly.
The paper, published in Toxicon, suggests that GLP-1 receptor agonists may reduce how long botulinum toxin type A lasts. In the model, predicted treatment duration was shorter in GLP-1 users than in controls across both neurological and aesthetic examples. The authors looked at agents including exenatide, liraglutide, dulaglutide, semaglutide and tirzepatide (Rahman et al., 2026).
That sounds dramatic, but here is the important bit.
This was not a real-world clinical trial.
This was a computational modelling paper, sometimes called an in silico study. In simple terms, that means the authors used a computer-based simulation to estimate what might happen under different conditions. That can be useful for spotting patterns and asking better questions, but it is not the same thing as proving the effect in real patients in clinic. The paper itself describes the findings as exploratory and says further validation is needed (Rahman et al., 2026).
So no, this does not prove that everyone on a GLP-1 medication will suddenly burn through Botox.
But it does raise a sensible question.
Why would GLP-1 medication affect anti-wrinkle results?
According to the paper, the model linked the possible shorter duration to changes in metabolism, lean mass, and neuromuscular recovery. The authors also suggested a possible interaction involving SNAP-25 phosphorylation, which is one of the pathways botulinum toxin relies on. In the simulation, tirzepatide showed the strongest shortening effect and semaglutide the least, but all of this still sits firmly in the “interesting early signal” category rather than settled fact (Rahman et al., 2026).
Translated into normal language: if someone is losing weight quickly, changing body composition, and going through a lot physiologically, it is not impossible that treatment longevity could shift too.
That is believable.
It is just not fully proven yet.
So, should people on Mounjaro, Wegovy or Ozempic worry?
Not panic, no.
But it is worth being aware of.
If someone is taking Mounjaro, Wegovy or Ozempic and notices that their anti-wrinkle treatment seems to wear off a bit faster than it used to, this paper gives one possible explanation worth keeping an eye on. It does not mean the treatment will not work. It does not mean the dose should automatically be increased. And it definitely does not mean everyone on a GLP-1 will have the same experience (Rahman et al., 2026).
It simply means this may become another factor to consider when looking at how long results last.
What should you do if you are on a GLP-1 and have Botox?
The sensible answer is very boring, but very true: track your own results properly.
If you are using a GLP-1 medication and having anti-wrinkle treatment, pay attention to:
- how quickly your treatment starts working
- how long the result seems to last
- whether this feels different from before
- whether you are also losing weight rapidly
- whether your face shape or muscle activity seems to be changing
That gives your injector something useful to work with at review, rather than guessing.
The real takeaway
This paper is interesting, and it is getting attention for a reason. It raises a genuine possibility that GLP-1 medications such as Mounjaro, Wegovy and Ozempic may shorten the durability of botulinum toxin treatments. But at the moment, that is still a theory supported by modelling, not a real-world clinical conclusion. The study itself says more validation is needed before treatment intervals or dosing practices are changed (Rahman et al., 2026).
So the sensible position right now is:
- interesting
- worth knowing about
- not proven enough to panic over
At Mr Beautox Aesthetics, this is exactly the sort of thing worth discussing properly at consultation or review, especially if someone feels their treatment is not lasting the way it used to.
If you are on a GLP-1 and wondering whether it could be affecting your anti-wrinkle results, feel free to get in touch via www.mrbeautox.co.uk, email hello@mrbeautox.co.uk, or message/call 07902 245304.
Written by Injector Rick at Mr Beautox Aesthetics, Worthing. Because sometimes the headline is dramatic, but the honest answer is a bit more nuanced.
Reference list
NHS (n.d.) Obesity – Treatment. Available at: https://www.nhs.uk/conditions/obesity/treatment/ (Accessed: 1 April 2026).
NHS England (n.d.) Weight management injections. Available at: https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ (Accessed: 1 April 2026).
NHS Frimley ICB (n.d.) Weight loss medications. Available at: https://frimley.icb.nhs.uk/your-health/lifestyle-factors/physical-activity-and-weight-management/weight-loss-medications (Accessed: 1 April 2026).
Rahman, E., Michon, A., Rao, P., Ahmed, M., Joseph, J.H., Wu, W.T.L., Carruthers, J.D.A. and Webb, W.R. (2026) ‘Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin A: Evidence for reduced treatment durability across neurologic and aesthetic indications’, Toxicon, 269, p. 108638.